TW201322986A - １８－甲基－６，７－亞甲基－３－氧基－１７－妊－４－烯－２１，１７β－羧內酯、包含該化合物之醫療製劑及其於治療子宮內膜異位症之用途 - Google Patents

１８－甲基－６，７－亞甲基－３－氧基－１７－妊－４－烯－２１，１７β－羧內酯、包含該化合物之醫療製劑及其於治療子宮內膜異位症之用途 Download PDF

Info

Publication number
TW201322986A
TW201322986A TW101140872A TW101140872A TW201322986A TW 201322986 A TW201322986 A TW 201322986A TW 101140872 A TW101140872 A TW 101140872A TW 101140872 A TW101140872 A TW 101140872A TW 201322986 A TW201322986 A TW 201322986A
Authority
TW
Taiwan
Prior art keywords
inhibitor
endometriosis
methyl
methylene
treatment
Prior art date
Application number
TW101140872A
Other languages
English (en)
Chinese (zh)
Inventor
珍 賀伯納
羅夫 鮑爾曼
伊莎貝拉 葛斯瓦
Original Assignee
拜耳製藥公司
拜耳知識產權公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2011/069464 external-priority patent/WO2012059594A1/en
Application filed by 拜耳製藥公司, 拜耳知識產權公司 filed Critical 拜耳製藥公司
Publication of TW201322986A publication Critical patent/TW201322986A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/007—3 membered carbocyclic rings in position 6-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW101140872A 2011-11-04 2012-11-02 １８－甲基－６，７－亞甲基－３－氧基－１７－妊－４－烯－２１，１７β－羧內酯、包含該化合物之醫療製劑及其於治療子宮內膜異位症之用途 TW201322986A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2011/069464 WO2012059594A1 (en) 2010-11-04 2011-11-04 Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
DE102012212838 2012-07-23

Publications (1)

Publication Number Publication Date
TW201322986A true TW201322986A (zh) 2013-06-16

Family

ID=48191408

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101140872A TW201322986A (zh) 2011-11-04 2012-11-02 １８－甲基－６，７－亞甲基－３－氧基－１７－妊－４－烯－２１，１７β－羧內酯、包含該化合物之醫療製劑及其於治療子宮內膜異位症之用途

Country Status (15)

Country Link
US (1) US20140288035A1 (enExample)
JP (1) JP2014532685A (enExample)
KR (1) KR20140088197A (enExample)
CN (1) CN103957921A (enExample)
AR (1) AR088622A1 (enExample)
AU (1) AU2012331089A1 (enExample)
BR (1) BR112014010590A2 (enExample)
CA (1) CA2854215A1 (enExample)
EA (1) EA201400537A1 (enExample)
HK (1) HK1199712A1 (enExample)
IL (1) IL232325A0 (enExample)
IN (1) IN2014CN03307A (enExample)
MX (1) MX2014005367A (enExample)
TW (1) TW201322986A (enExample)
WO (1) WO2013064620A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CN117417303B (zh) * 2023-10-19 2024-07-09 黑龙江中医药大学 一种用于治疗子宫内膜异位症的药物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1183500B (de) 1962-10-12 1964-12-17 Schering Ag Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe
FR1529949A (fr) 1966-05-19 1968-06-21 American Home Prod Composés stéroïdes tels que 10-méthylgon-4-en-3-ones et leurs dérivés
DE1921396C3 (de) 1969-04-23 1978-04-27 Schering Ag, 1000 Berlin Und 4619 Bergkamen 17 a-Hydroperoxy-16 a, 18-dimethyl-20ketosteroide, Verfahren zur Herstellung derselben, sowie weitere entsprechende Zwischenprodukte
DE2922500A1 (de) 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
DE19633685C1 (de) * 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
ATE442147T1 (de) 2000-01-18 2009-09-15 Bayer Schering Pharma Ag Pharmazeutische zubereitung enthaltend drospirenon
CL2004000574A1 (es) * 2003-03-21 2005-02-11 Pharmacia Corp Sa Organizada B Proceso para preparar un compuesto 17-espirolactona o la sal de lactona abierta por carbonilacion del correspondiente 17-alquenil o alquinil derivado, los intermediarios que se usan y su proceso de obtencion.
DE102007011105A1 (de) 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
WO2012059594A1 (en) * 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity

Also Published As

Publication number Publication date
AU2012331089A1 (en) 2014-05-22
IL232325A0 (en) 2014-06-30
CA2854215A1 (en) 2013-05-10
MX2014005367A (es) 2014-07-09
BR112014010590A2 (pt) 2017-05-02
CN103957921A (zh) 2014-07-30
IN2014CN03307A (enExample) 2015-07-03
HK1199712A1 (en) 2015-07-17
US20140288035A1 (en) 2014-09-25
EA201400537A1 (ru) 2014-10-30
AR088622A1 (es) 2014-06-25
KR20140088197A (ko) 2014-07-09
WO2013064620A1 (de) 2013-05-10
JP2014532685A (ja) 2014-12-08

Similar Documents

Publication Publication Date Title
TW201322986A (zh) １８－甲基－６，７－亞甲基－３－氧基－１７－妊－４－烯－２１，１７β－羧內酯、包含該化合物之醫療製劑及其於治療子宮內膜異位症之用途
FI112167B (fi) Dissosioituneiden kilpailevien progesteroniantagonistien käyttö ehkäisyaineen valmistamiseksi ja käyttökelpoisia uusia yhdisteitä
JP2013504531A (ja) 抗癌薬としての置換（ヘテロアリールメチル）チオヒダントイン
US20040087563A1 (en) Hormone replacement therapy with cardiovascular protection using antialdosteronic progestins
US20220143045A1 (en) Progesterone receptor antagonist dosage form
TW200900080A (en) Mineralcorticoid receptor antagonists for the treatment of endometriosis
TW201827053A (zh) 凝乳酶抑制劑用於治療子宮內膜異位、手術後纖維化及以纖維化表徵之病症之用途
AU2016294185B2 (en) Estrogen receptor β partial agonist having estrogen receptor α inhibitory effect, and therapeutic agent for gynecological disorders using same
Hapangama Mifepristone: the multifaceted antihormone
TW200927137A (en) Compositions and methods for treating dysfunctional uterine bleeding
WO2004041288A1 (en) Hormone replacement therapy with drospirenone
HK40010025A (en) Progesterone receptor antagonist dosage form
EP2773356A1 (de) 18-methyl-6,7-methylen-3-oxo-17-pregn-4-en-21,17 -carbolactone, pharmazeutische präparate enthaltend die genannten verbindungen und deren anwendung bei der therapie der endometriose
JPH07188026A (ja) ジエノゲストを有効成分とするホルモン療法用制癌剤
NZ712670B2 (en) Progesterone receptor antagonist dosage form
NZ750686B2 (en) Progesterone receptor antagonist dosage form
NZ750686A (en) Progesterone receptor antagonist dosage form
HK1171191A (en) Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
HK1155085A (en) Progesterone antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc